Fibroblast activation protein (FAP) is a
serine protein that is selectively expressed in pathologic sites in the
adults making it a target specific site for many therapeutic agents.
Fibroblast activation protein (FAP) is expressed during tissue
remodeling stage in embryonic development. However, in adults,
fibroblast activation protein (FAP) is expressed in specific sites like
cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc.
Fibroblast activation protein is widely believed to be expressed on
stromal fibroblasts of epithelial cancer cells and promotes cancer cell
growth and metastasis. The specificity of fibroblast activation protein
offers potential to represent as a new drug target in the diagnosis and
treatment of cancer. Various clinical trials are being conducted to
assess the potential of treating cancer by inhibiting the fibroblast
activation protein. Cancer cells are often very sensitive to growth
factors. Development of cancer growth impeders such as fibroblast
activation protein (FAP) inhibitors can provide promising results in
cancer management.
Fibroblast activation protein (FAP) have
similar specificity as dipeptidyl peptidases (DPPs) and prolyl
oligopeptidase (PREP) which are also known to elevate in cancers. This
leads to the need of development of inhibitors that are specific to
fibroblast activation protein (FAP).
Huge opportunities lie in development of
fibroblast activation protein (FAP) specific inhibitors. Vigorous
research and development programs are being conducted for the
development of such inhibitors. One such inhibitor is Val-boroPro
(Talabostat) which is a single-agent inhibitor of fibroblast activation
protein (FAP) enzymatic activity. A number of clinical trials have been
conducted to assess the efficacy of talabostat as fibroblast activation
protein (FAP) inhibitor in different cancers such as colorectal, lung,
pancreatic, leukemia and melanoma. Another approach being used in
developing fibroblast activation protein (FAP) inhibitor is monoclonal
antibodies. However, such approaches have not been extensively used in
the clinical setting, mainly due to absence of effective actions.
Due to the rise in the prevalence of
cancer globally, fibroblast activation protein (FAP) inhibitors are
anticipated to assist in prevention of proliferation of these
carcinogenic cells. According to the National Cancer Institute, an
estimated 1,685,210 new cases of cancer will be detected in 2016 in the
U.S alone. The most common ones are breast cancer, prostate cancer,
colon and rectum cancer, lung and bronchus cancer, bladder cancer,
melanoma, kidney and renal pelvis cancer, leukemia, and pancreatic
cancer. Of these colorectal cancer is the third most common type of
cancer in the world. This cancer is a result of uninhibited cell
progression that occurs in the appendix, colon, and the rectum region.
The common symptoms of colorectal cancer are bleeding in the stool,
weight loss, fatigue, and irregular bowel movements. According to the
World Cancer Research Fund International, approximately 1.5 million new
cases of colorectal cancer are detected each year. Many clinical trials
are being conducted to discover novel methods to treat colorectal cancer
through fibroblast activation protein (FAP) inhibitors.
The increasing worldwide prevalence of
various cancers, including breast cancer, colorectal cancer, prostate
cancer, skin cancer, blood cancer, gastrointestinal tract cancer, and
lung cancer, is the prime factor heightening the demand for anti-cancer
drugs. In addition to this, the improvement of advanced therapeutic
approaches, such as targeted therapies, immunotherapy, radiotherapy, and
chemotherapy has significantly benefited the anti-cancer drugs market
in recent years. Although not much progress has been made in fibroblast
activation protein (FAP) inhibitors discovery for treating various
cancer, this field possesses huge research and development opportunities
in the near future.
The report offers a comprehensive
evaluation of the market. It does so via in-depth insights,
understanding market evolution by tracking historical developments, and
analyzing the present scenario and future projections based on
optimistic and likely scenarios. Each research report serves as a
repository of analysis and information for every facet of the market,
including but not limited to: Regional markets, technology developments,
types, applications, and the competitive landscape.
No comments:
Post a Comment